Unlike everyday supplements stocked in every health store, CJC-1295 is distributed via a global research peptide market that Léma residents reach through online vendors. The benefit of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers better verification tools than any physical store could provide. What consistently distinguishes top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for contamination assurance. The sections below cover what Léma researchers need to know about purchasing, testing, and working with CJC-1295 for legitimate research applications.
What Studies Say About CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Léma researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Vetting CJC-1295 vendors begins with the COA: request the batch-specific certificate before purchasing, not after. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone does not confirm what the compound actually is. Negative indicators in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, vague sourcing information, no community presence, and COAs that omit endotoxin testing. Price is an ineffective primary criterion for CJC-1295 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so significantly below-market pricing signals compromises.
Order CJC-1295 — ships to Léma
COA-verified · International tracking · Research grade
All use of CJC-1295 in Léma or anywhere constitutes research use — this compound is not approved for clinical human use, and all handling should adhere to research compound handling standards. Lyophilised CJC-1295 should be frozen at −20°C as soon as it arrives; repeated freeze-thaw cycles of reconstituted material should be avoided by preparing small aliquots before storage. Verify the endotoxin level in your CJC-1295 batch COA before any injectable research application — look for results expressed as EU/mg or EU/mL and compare against acceptable research limits for your application. Researchers combining CJC-1295 with other compounds should review the available literature for documented interactions before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
